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AP1S3 Mutations Are Associated with Pustular Psoriasis
and Impaired Toll-like Receptor 3 Trafficking
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Adaptor protein complex1 (AP-1) is an evolutionary conservedheterotetramer that promotes vesicular traffickingbetween the trans-Golgi
network and the endosomes. The knockout ofmostmurineAP-1 complex subunits is embryonically lethal, so the identificationof human
disease-associated alleles has the uniquepotential to deliver insights into gene function.Here, we report two foundermutations (c.11T>G
[p.Phe4Cys] and c.97C>T [p.Arg33Trp]) inAP1S3, the gene encodingAP-1 complex subunits1C, in 15unrelated individualswith a severe
autoinflammatory skin disorder known as pustular psoriasis. Because the variants are predicted to destabilize the 3D structure of the AP-1
complex, we generated AP1S3-knockdown cell lines to investigate the consequences of AP-1 deficiency in skin keratinocytes. We found
that AP1S3 silencing disrupted the endosomal translocation of the innate pattern-recognition receptor TLR-3 (Toll-like receptor 3) and
resulted in a marked inhibition of downstream signaling. These findings identify pustular psoriasis as an autoinflammatory phenotype
caused by defects in vesicular trafficking and demonstrate a requirement of AP-1 for Toll-like receptor homeostasis.Adaptor protein (AP) complexes are cytosolic heterote-
tramers that promote the assembly and trafficking of small
transport vesicles. Each of the five known complexes (AP-1,
AP-2, AP-3, AP-4, and AP-5) is active in a distinct subcel-
lular compartment, where it mediates the delivery of trans-
membrane proteins to specific target organelles.1 AP-1 is
involved in the transport of cargoes between the trans-Golgi
network and the endosomes, a process that requires the for-
mation of specialized clathrin-coated vesicles. Similar to
other AP complexes, AP-1 consists of two large (g and b1),
one medium (m1), and one small (s1) subunit. These are
the product of eight genes, which encodemultiple isoforms
of the b1 (b1A and b1B), m1 (m1A and m1B), and s1 (s1A,
s1B, and s1C) subunits.2 Of note, the knockout of genes
encoding the murine AP-1 g and m1A subunits is embryon-
ically lethal.3 Although this observation underscores the
crucial role of AP-1 in cell homeostasis, it also highlights
the difficulty of investigating its function in vivo.
The term pustular psoriasis indicates a group of rare and
severe inflammatory skin disorders that often manifest
with concomitant plaque psoriasis. Generalized pustular
psoriasis (GPP [MIM 614204]) is the most severe form
of the disease and is characterized by acute, potentially
life-threatening episodes of skin pustulation and sys-
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chronic, localized, and disabling conditions that affect the
palms and soles (PPP) or the tips of the fingers and toes
(ACH).4
We and others have identified recessive mutations in
IL36RN (MIM 605507), the gene encoding IL-36 receptor
antagonist, in individuals affected by GPP, ACH, and
PPP, thus demonstrating a shared genetic basis for acute
and chronic forms of pustular psoriasis.5–7 Importantly,
IL36RN defects are only found in a minority of affected
individuals,8 an observation that underscores our limited
understanding of disease pathogenesis.
Here, we report the identification of pustular psoriasis
mutations in AP1S3 (RefSeq accession number NM_
001039569.1), the gene encoding the s1C subunit of the
AP-1 complex.
We undertook the search for disease-causing mutations
by means of whole-exome sequencing. To minimize the
confounding effects of genetic heterogeneity, we focused
on a single disease subtype and examined seven isolated
ACH subjects (individuals S0655–S0661 in Table 1;
Figure 1A). The study was approved by the research ethics
committees of the contributing institutions, and all partic-
ipants granted their written informed consent. Whole-
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Table 1. ACH Subjects Analyzed by Whole-Exome Sequencing
Subject ID Sex Origin Plaque Psoriasis GPP Age of Onset (Years)
S0125 female British no yes 10
S0128 female British no yes 45
S0655 female Polish yes no 57
S0656 female Swiss yes no 76
S0657 female Swiss no no 82
S0658 male Swiss no no 49
S0659 female Irish no no 54
S0660 female Swiss yes no 56
S0661 female British no no 39
All subjects were negative for mutations in IL36RN and CARD14, a locus that has been tentatively implicated in the pathogenesis of GPP.9 Individuals S0125 and
S0128 had been previously exome sequenced by our group.6XT Human All Exome Kit (v.4), and enriched DNA
fragments were sequenced on an Illumina HiSeq2000
apparatus. Paired-end reads were aligned to the hg19 refer-
ence genome (UCSC Genome Browser) with Novoalign
(v.2.07.17, Novocraft Technologies). Over 8.2 Gb of
sequence was obtained for each subject, so that >90% of
Gencode bases were covered at a depth exceeding 203
(Table S1, available online). Single-nucleotide substitu-
tions and small indels were identified with Samtools
(v.0.1.18)10 and annotated to coding genes with the
ANNOVAR package (October 2012 release).11 The variant
profiles thus generated were merged with those of two
individuals affected by ACH with concomitant GPP
(S0125 and S0128 in Table 1), who were previously exome
sequenced by our group.6 The combined data set wasFigure 1. Identification of AP1S3 Mutations in Individuals Affected
(A) Clinical presentation of ACH with active sterile pustules, scaling
(B) Protein sequence alignments demonstrating the evolutionary co
(C) Representative chromatograms of the c.11T>G (p.Phe4Cys) and
change is highlighted by an asterisk.
The Amfiltered for removal of all synonymous changes and all
polymorphisms occurring with >1% frequency in the
1000 Genomes CEU (Utah residents with ancestry from
northern and western Europe) data set, the NHLBI Exome
Sequencing Project Exome Variant Server, or 1,360 exomes
sequenced in house. This identified an average of 485 pro-
tein-altering changes per sample (Table S2).
No gene harbored rare homozygous or compound-
heterozygous alleles in more than one affected individual.
Conversely, 13 loci showed heterozygous changes in four
outofnine subjects (Table S3). Theuseofpathogenicity-pre-
diction software (SIFT12 and PolyPhen-213 for coding alleles
and MaxEntScan14 and Spliceman15 for splicing variants)
indicated that only two genes, AP1S3 and MYOM1 (MIM
603508), encompassed variation classified as deleteriousby Pustular Psoriasis
, nail dystrophy, and digit tapering.
nservation of the Phe4 and Arg33 residues.
c.97C>T (p.Arg33Trp) mutations. The position of the nucleotide
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Table 2. Frequency Distribution of Rare AP1S3 Variants
Variant (rs ID)
Pathogenicity Prediction Allele Counts (%)
p ValueSIFT PolyPhen-2 PROVEAN MutationTaster MutPred Consensusa Cases Controlsb
c.11T>G (p.Phe4Cys)
(rs116107386)
damaging probably
damaging
deleterious disease causing damaging DAMAGING 6/256 (2.3%) 22/3,390
(0.6%)
0.01
c.49C>A (p.Gln17Lys) tolerated possibly
damaging
deleterious disease causing neutral NEUTRAL 0/256 (0%) 1/3,388
(0.02%)
0.09
c.64A>G (p.Thr22Ala)
(rs149183052)
damaging benign neutral disease causing neutral NEUTRAL 0/256 (0%) 16/3,322
(0.5%)
0.54
c.95C>T (p.Thr32Ile)
(rs78536455)
tolerated benign deleterious polymorphism neutral NEUTRAL 1/256 (0.4%) 16/3,388
(0.5%)
0.77
c.97C>T (p.Arg33Trp)
(rs138292988)
damaging probably
damaging
deleterious disease causing damaging DAMAGING 9/256 (3.6%) 24/3,388
(0.7%)
2.3 3 105
c.235T>G (p.Leu79Val)
(rs34353588)
tolerated benign neutral disease causing neutral NEUTRAL 0/256 (0%) 4/3,390
(0.1%)
0.66
c.248T>C (p.Ile83Thr)
(rs202157374)
tolerated benign deleterious disease causing neutral NEUTRAL 0/256 (0%) 5/3,390
(0.1%)
0.79
Damaging variantsa 15/256 (5.9%) 46/3,388
(1.4%)
2.5 3 107
aVariants were designated as damaging when a high-confidence pathogenicity prediction was returned by at least four out of five programs. All pathogenicity
predictions are based on the analysis of AP1S3 transcript ENST00000396654.
bThe differences in total allele counts reflect the varying coverage of the relevant nucleotides in the control individuals who were exome sequenced.bymultiple algorithms.Given that the four subjects bearing
an AP1S3 variant all carried the same rare allele (c.97C>T
[p.Arg33Trp]), we selected this locus for follow-up. We
screened 119 unrelated British individuals (112 with PPP,
five with GPP, and two with ACH; Tables S4 and S5) and
detected the c.97C>T allele in five additional subjects
(four with PPP and one with GPP). Moreover, we identified
six subjects (fivewith PPP and onewithGPP)whoharbored
a c.11T>G (p.Phe4Cys) mutation (Figure 1B and 1C). Thus,
AP1S3 variants were found in all forms of pustular psoriasis
but were noticeably enriched among ACH-affected subjects
and significantly underrepresented within the PPP data set
(Tables S6 and S7).
To further explore the significance of these results,
we assessed the frequency and pathogenic potential of
the rare AP1S3 alleles observed in 1,695 unrelated control
individuals (Table S8). Although we observed seven coding
variants occurring with <1% frequency, we found that
c.11T>G and c.97C>T were the only changes predicted to
be pathogenic. Importantly, the frequencies of both alleles
were significantly higher in pustular psoriasis subjects than
in the general population: the c.11T>Gmutation appeared
in 2.3% of affected individuals, but only 0.6% of control
subjects (p ¼ 0.01), and c.97C>T appeared in 3.6% of
affected individuals, but only 0.7% of control subjects
(p ¼ 2.3 3 105). The combined analysis of the two muta-
tions yielded p ¼ 2.5 3 107 (Table 2), exceeding the
threshold for exome-wide significance (p < 2.5 3 106).16
To investigate whether AP1S3mutations were also found
in individuals of non-European descent, we analyzed 72
Asian (all with GPP) and four African (two with ACH and
two with GPP) subjects. In keeping with the population
frequencies documented by the 1000 Genomes Project,792 The American Journal of Human Genetics 94, 790–797, May 1, 2we found that none of the above subjects carried the
c.11T>G or c.97C>T allele. We observed no other AP1S3
coding variant, with the exception of a heterozygous
c.370C>G (p.Gln124Glu) mutation, found in a single
Malay subject and predicted to be benign. Thus, our find-
ings indicate that pustular psoriasis is specifically associ-
ated with the c.11T>G and c.97C>T alleles.
We next sought to determine whether the two muta-
tions were the result of a founder effect. Because the late
age of disease onset hindered the collection of parental
samples, we focused our analysis on the affected subjects,
whom we genotyped for a highly polymorphic intragenic
(TG) repeat. We found that all c.97C>T subjects were het-
erozygous for a 214 bp allele, whereas all c.11T>G individ-
uals carried a 218 bp repeat. Given the low population
frequency of the 214 and 218 bp alleles, this observation
strongly suggests that c.97C>T and c.11T>G are founder
mutations and argues against the possibility of de novo
inheritance (Table 3). In keeping with these findings, segre-
gation analyses carried out in two representative pedigrees
confirmed that the probands (T002206 and T001882,
bearing c.11T>G and c.97C>T, respectively) had inherited
the disease allele from an unaffected parent. Thus, the lack
of family history among subjects with AP1S3 mutations
(Table S6) is likely to reflect the requirement of environ-
mental triggers for disease development. Indeed, it is well
recognized that pustular flares are often initiated by infec-
tions, pregnancy, or drug exposure.4
To explore the consequences of the p.Phe4Cys
(c.11T>G) and p.Arg33Trp (c.97C>T) changes, we
modeled the structure of AP-1 subunit s1C (encoded by
AP1S3) with the Modeler 9 (v.8.0) package.17 We used the
T-Coffee software (v.1.0)18 to align the sequence of AP-1014
Table 3. Association between Intron 1 Repeats and AP1S3 Mutations
214 bp Repeat 218 bp Repeat
UK Populationa c.97C>T Subjects UK Populationa c.11T>G Subjects
Allele counts (frequency) 18/278 (6.5%) 9/18 (50%) 17/278 (6.1%) 6/12 (50%)
Association p ¼ 7.0 3 109 p ¼ 6.9 3 107
aA sample of 139 unrelated British individuals genotyped in house.subunit s1C with that of the murine AP-1 core19 (Protein
Data Bank ID 1W63), generating 200 models. We selected
those with the best Modeler DOPE scores and visualized
the p.Phe4Cys and p.Arg33Trp substitutions by using
PyMol (v.1.3 Schro¨dinger). We also modeled the interac-
tion between AP-1 subunit s1C and its partner m1A by
superimposing human s1C coordinates on the structure
of the murine AP-1 s1C/m1A crystal complex.
We found that Phe4 is located within the core of AP-1
subunit s1C and is part of a cluster of hydrophobic resi-
dues, which stabilize the protein and its fold (Figure 2A,
top panel). Importantly, the p.Phe4Cys substitution causes
the loss of crucial contacts with residues Ile35 and Trp52
and has a likely detrimental effect on the stability of the
complex (Figure 2A, bottom panel). We further observed
that Arg33 is critically located at the AP-1 s1C/m1A inter-
face, where the substitution of a positively charged argi-
nine with a nonpolar tryptophan is likely to disrupt a
salt bridge with Glu232 of AP-1 subunit m1A and substan-
tially weaken the interaction between the two subunits
(Figure 2B). In keeping with these predictions, we observed
decreased levels of the p.Phe4Cys protein upon transfec-
tion of mutant and wild-type (WT) constructs into human
embryonic kidney 293 (HEK293) and HaCaT cells. This
reduction in AP-1 subunit s1C accumulation was not
observed when a construct encoding the p.Arg33Trp
change was transfected, supporting the notion that the
p.Phe4Cys substitution specifically disrupts protein stabil-
ity and folding, whereas p.Arg33Trp is more likely to exert
its effect on protein-protein interactions (Figures 2C, 2D,
and S1).
Given that AP-1 subunit s1C is one of the core subunits
thought to stabilize AP-1 heterotetramers,3 we reasoned
that p.Phe4Cys and p.Arg33Trp are likely to be loss-of-
function changes disrupting the formation of functional
AP-1 complexes. Given that the endosomal localization
of the innate receptors TLR-7 and TLR-9 is dependent on
AP-2 and AP-4,21 we further hypothesized that AP-1 might
be required for the trafficking of the paralog TLR-3 recep-
tor. Thus, we proposed that AP1S3 deficiency would
disrupt TLR-3 translocation to the endosome and result
in abnormal downstream signaling.
To explore this hypothesis, we generated two stable
AP1S3-knockdown cell lines (Figure 3A) through the lenti-
viral transduction of HaCaT immortalized keratinocytes
with targeted small hairpin RNA (shRNA) constructs
(Table S9). Because TLR-3 is cleaved by acidic proteasesThe Amupon reaching the endosomes,22 we investigated the
effects of AP1S3 silencing by monitoring the levels of
full-length and processed receptor. We found that TLR-3
trafficking was disrupted in both knockdown cell lines,
where the ratio between endosomal and newly synthe-
sized receptor was markedly reduced. This effect was
already noticeable under basal conditions but became
more pronounced upon stimulation of TLR-3 with the
poly(I:C) ligand (Figure 3B, lanes 2, 4, and 6).
To further explore these findings, we sought to deter-
mine whether AP1S3 deficiency also affects TLR-3-depen-
dent induction of genes encoding type I interferons
(IFNs). We stimulated control and knockdown cell lines
with poly(I:C) and measured IFNB1 expression by real-
time PCR. In keeping with the results of the previous ex-
periments, we found that the induction of IFNB1 tran-
scripts was virtually abolished in one knockdown cell
line and significantly reduced in the second (Figure 3C).
Having demonstrated that AP1S3 knockdown disrupts
TLR-3 endosomal translocation, we sought to determine
whether disease-associated alleles have a similar impact.
We reasoned that the p.Phe4Cys change would very likely
mimic the effects of gene silencing, given its deleterious
impact on protein stability. We therefore focused our
attention on the c.97C>T (p.Arg33Trp) mutation. We
generated another AP1S3-knockdown cell line by silencing
gene expression in HEK293 cells (Figure 3D). In keeping
with the results obtained in HaCaT keratinocytes, we
were able to show that AP1S3 deficiency resulted in
reduced processing of transfected TLR-3 (Figure 3E, left
panel). Having validated this experimental system, we
investigated the effects of overexpressing WT versus
mutant constructs. We found that the transfection of
cDNAs encoding the p.Arg33Trp substitution resulted in
decreased accumulation of N-ter TLR-3 (Figure 3E, right
panel), demonstrating a significant impact on protein
function for this disease allele.
The devastating consequences of AP-1 deficiency
have been documented in mice3 and in humans, where
recessive truncating mutations in AP1S1 cause MEDNIK
syndrome (mental retardation, enteropathy, deafness, pe-
ripheral neuropathy, ichthyosis, and keratodermas [MIM
609313]), a congenital multisystem disorder associated
with reduced life expectancy.23 Thus, the pleiotropic ef-
fects of AP-1 deficiency have hindered the identification
of specific cellular processes that are controlled by this
complex. Although the knockout of genes encoding AP-2erican Journal of Human Genetics 94, 790–797, May 1, 2014 793
Figure 2. Structural Impact of the p.Phe4Cys and p.Arg33Trp Substitutions
(A) Comparison between WT (AP-1 s1CWT, cyan) and p.Phe4Cys (AP-1 s1Cp.Phe4Cys, blue) proteins. The residues within 6 A˚ of AP-1
s1CWT Phe4 and AP-1 s1Cp.Phe4Cys Cys4 are shown in stick representation and are colored in light green and green, respectively. The
hydrophobic interactions between Phe4 and its neighboring residues are represented by red dotted lines.
(B) Comparison between WT (AP-1 s1CWT, cyan) and p.Arg33Trp (AP-1 s1Cp.Arg33Trp, orange) proteins. AP-1 s1C residues Arg33 and
Trp33, together with AP-1 s1A residue Glu232 (which lies within 6 A˚ of Arg33), are shown in stick representation.
(C) Immunoblot demonstrating the reduced accumulation of p.Phe4Cys proteins. WT and mutant pcDNA3.1-Myc-AP1S3 constructs
were transfected alongside a pcDNA3.1-Myc-RNF114 plasmid (which was used as a transfection-efficiency and loading control) into
HEK293 cells. Protein extracts were analyzed by immunoblot with an anti-Myc antibody (MA1-21316, 1:1,000 dilution, Thermo
Scientific). The image is representative of the results obtained in two independent transfections.
(D) Densitometric analysis of the immunoblots described in (C). The ratio between the intensities of the AP-1 s1C and RNF114 bands
was derived with ImageJ.20 Data are shown as means5 SD of two independent experiments. *p < 0.05 (unpaired t test).subunits is also embryonically lethal,3 heterozygous
missense mutations in AP2S1 (MIM 602242; encoding
AP-2 subunit s2) have been associated with reduced cal-
cium-sensing receptor endocytosis, which leads to familial
hypocalciuric hypercalcemia (MIM 600740).24 This sug-
gests that the characterization of missense changes in
genes encoding AP-1 and AP-2 could help dissect the
cellular pathways that are affected by the disruption of
each AP complex.
Here, we describe two heterozygous AP1S3 mutations
resulting in severe skin autoinflammation. Our analysis
of 128 European and 76 non-European affected individuals
has demonstrated that the disease is specifically associated
with substitutions in residues Phe4 and Arg33, suggesting
a crucial role for these two amino acids. This notion is
supported by our structural biology findings and overex-794 The American Journal of Human Genetics 94, 790–797, May 1, 2pression experiments, which indicate that p.Phe4Cys
and p.Arg33Trp are likely to have a detrimental effect on
AP-1 function.
To explore the consequences of AP-1 deficiency in skin,
we silenced AP1S3 expression in HaCaT immortalized
keratinocytes and HEK293 cells. We found that AP1S3
knockdown was consistently associated with a significant
reduction in TLR-3 trafficking. Moreover, we demonstrated
that TLR-3-mediated IFNB1 induction was markedly
decreased in AP1S3-knockdown HaCaT keratinocytes.
Importantly, IFN-b (the cytokine encoded by IFNB1) has
well-documented anti-inflammatory functions, as demon-
strated by its protective effect in several autoimmune
conditions.25,26 IFN-b also downregulates the production
of interleukin-1 (IL-1),25 the cytokine driving the patho-
genesis of most autoinflammatory conditions.27 Thus,014
Figure 3. AP1S3 Deficiency Affects TLR-3
Trafficking and Downstream Signaling
(A) Stable AP1S3 knockdown in HaCaT
immortalized keratinocytes. Approxi-
mately 3 3 105 HaCaT cells were trans-
duced with the supernatants of HEK293
cultures (5 3 105 cells) transfected with
10 mg packaging plasmids (2 mg VSV-G
and 8 mg p8.91, Addgene 8454 and 8455)
and 2 mg control (ctr; nonsilencing) or
silencing shRNA construct. After selection
in 10 mg/ml puromycin, the knockdown
efficiency was measured by real-time PCR
(Table S5) with PPIA expression as an inter-
nal control (Life Technologies TaqMan
assay 4326316E). Data are presented as
mean 5 SD of two independent RNA ex-
tractions. ***p < 0.001 (unpaired t test).
(B) AP1S3 knockdown disrupted traf-
ficking of endogenous TLR-3 in HaCaT ker-
atinocytes. Control and knockdown cells
were stimulated with 25 mg/ml poly(I:C)
(Invivogen) for 18 hr. The amounts of
endosomal (N-ter fragment) and newly
synthesized (full-length [FL]) TLR-3 were
assessed by immunoblotting with Thermo
Fisher Scientific PA5-20184 antibody
(1:500 dilution). The intensities of the
two bands were measured with ImageJ,
and the ratio between the N-ter and FL iso-
forms was determined for each sample.
Bold, underlined font indicates the N-ter/
FL ratios observed after poly(I:C) stimula-
tion. b-actin levels determined with Cell
Signaling antibody 4970 (1:1,000 dilution)
are shown as a loading control.
(C) AP1S3 knockdown resulted in reduced
TLR-3 signaling. Control and knockdown
cells were stimulated with 25 mg/ml
poly(I:C) for 3 hr, and IFNB1 induction
was measured by real-time PCR (Life Tech-
nologies TaqMan assay 4331182) with
PPIA expression as an internal control. The data are representative of the results obtained in at least two independent experiments
and are shown as mean5 SD of two technical duplicates. **p < 0.01 (unpaired t test).
(D) Stable AP1S3 knockdown in HEK293 cells. Approximately 3 3 105 cells were transduced with lentiviral shRNA, as described above.
The knockdown efficiency was measured by real-time PCR with PPIA expression as an internal control. Data are presented as mean5 SD
of technical triplicates. **p< 0.001 (unpaired t test). The following abbreviation is used: ctr, control cells transduced with a nonsilencing
shRNA.
(E) Compared to AP1S3-knockdown cells overexpressing WT AP-1 s1C, AP1S3-knockdown cells overexpressing p.Arg33Trp protein
showed reduced TLR-3 processing. Left panel: control and knockdown HEK293 cells were transfected with TLR3 cDNA (Addgene
13084) for 48 hr. The amounts of endosomal (N-ter) and newly synthesized (FL) receptor were assessed by immunoblotting, and the ratio
between the two isoforms was determined by densitometry. Right panel: knockdown HEK293 cells were transfected with WTor mutant
AP1S3 cDNA constructs (encoding Arg33 or Trp33, respectively) for 24 hr and with TLR3 cDNA for a further 48 hr. The amounts of N-ter
and FL receptor were monitored by immunoblotting and densitometry. b-actin levels are shown as a loading control. The images are
representative of the results obtained from two independent experiments.our findings raise the intriguing possibility that the
reduced IFN response associated with AP1S3 mutations
results in enhanced IL-1 production upon exposure to
inflammatory stimuli. Of interest, none of the exome-
sequenced subjects lacking AP1S3 mutations carried any
rare variants in other genes encoding AP-1 subunits, indi-
cating that defects in other components of the complex
might have distinct phenotypic consequences.
Given the variety of cargoes that are trafficked by the
AP-1 complex, alleles associated with pustular psoriasis
are likely to affect the localization of additional molecules
other than TLR-3. In fact, experiments carried out in HeLaThe Amcells have demonstrated that AP-1 depletion causes the
deficiency of numerous proteins contributing to epidermal
homeostasis (e.g., desmoplakin and clathrin interactor 1)
and neutrophil function (e.g., PTPN9 and VPS45).28
Thus, fully characterizing the impact of AP1S3 mutations
on immune responses will require additional in vitro and
ex vivo studies. Given that treatment with IL-1 blockers
appears to be beneficial in at least some cases of pustular
psoriasis,29,30 experiments focusing on IL-1 signaling
deregulation would be of particular interest because they
could deliver important insights into the workings of a
druggable disease pathway.erican Journal of Human Genetics 94, 790–797, May 1, 2014 795
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